Strategies for in vivo siRNA delivery in cancer

Angela Sanguino; Gabriel Lopez-Berestein; Anil K. Sood

doi:10.2174/138955708783744074

Strategies for in vivo siRNA delivery in cancer

Angela Sanguino, Gabriel Lopez-Berestein, Anil K. Sood

Research output: Contribution to journal › Review article › peer-review

30 Scopus citations

Abstract

A better understanding of the mechanisms involved in small interference RNA (siRNA) gene silencing opens new horizons for the development of the targeted therapy of malignant and benign diseases. As a research tool, siRNA has proven to be highly effective in silencing specific genes and modulating intracellular signaling pathways. However, systemic delivery of siRNA has been more problematic due to degradation and poor cellular uptake. In order to overcome these limitations, a variety of strategies are being developed including new delivery vehicles and chemical modifications. Here, we review potential approaches for the systemic delivery of siRNA for cancer treatment.

Original language	English (US)
Pages (from-to)	248-255
Number of pages	8
Journal	Mini-Reviews in Medicinal Chemistry
Volume	8
Issue number	3
DOIs	https://doi.org/10.2174/138955708783744074
State	Published - Mar 2008

Keywords

Antibodies
Folate receptor
Polyethylene glycol
Positively charged polymers
SiRNA sequences

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Drug Discovery
Cancer Research

Access to Document

10.2174/138955708783744074

Cite this

@article{599645a20fab43019fa926fe75210d30,

title = "Strategies for in vivo siRNA delivery in cancer",

abstract = "A better understanding of the mechanisms involved in small interference RNA (siRNA) gene silencing opens new horizons for the development of the targeted therapy of malignant and benign diseases. As a research tool, siRNA has proven to be highly effective in silencing specific genes and modulating intracellular signaling pathways. However, systemic delivery of siRNA has been more problematic due to degradation and poor cellular uptake. In order to overcome these limitations, a variety of strategies are being developed including new delivery vehicles and chemical modifications. Here, we review potential approaches for the systemic delivery of siRNA for cancer treatment.",

keywords = "Antibodies, Folate receptor, Polyethylene glycol, Positively charged polymers, SiRNA sequences",

author = "Angela Sanguino and Gabriel Lopez-Berestein and Sood, {Anil K.}",

year = "2008",

month = mar,

doi = "10.2174/138955708783744074",

language = "English (US)",

volume = "8",

pages = "248--255",

journal = "Mini-Reviews in Medicinal Chemistry",

issn = "1389-5575",

publisher = "Bentham Science Publishers B.V.",

number = "3",

}

TY - JOUR

T1 - Strategies for in vivo siRNA delivery in cancer

AU - Sanguino, Angela

AU - Lopez-Berestein, Gabriel

AU - Sood, Anil K.

PY - 2008/3

Y1 - 2008/3

N2 - A better understanding of the mechanisms involved in small interference RNA (siRNA) gene silencing opens new horizons for the development of the targeted therapy of malignant and benign diseases. As a research tool, siRNA has proven to be highly effective in silencing specific genes and modulating intracellular signaling pathways. However, systemic delivery of siRNA has been more problematic due to degradation and poor cellular uptake. In order to overcome these limitations, a variety of strategies are being developed including new delivery vehicles and chemical modifications. Here, we review potential approaches for the systemic delivery of siRNA for cancer treatment.

AB - A better understanding of the mechanisms involved in small interference RNA (siRNA) gene silencing opens new horizons for the development of the targeted therapy of malignant and benign diseases. As a research tool, siRNA has proven to be highly effective in silencing specific genes and modulating intracellular signaling pathways. However, systemic delivery of siRNA has been more problematic due to degradation and poor cellular uptake. In order to overcome these limitations, a variety of strategies are being developed including new delivery vehicles and chemical modifications. Here, we review potential approaches for the systemic delivery of siRNA for cancer treatment.

KW - Antibodies

KW - Folate receptor

KW - Polyethylene glycol

KW - Positively charged polymers

KW - SiRNA sequences

UR - http://www.scopus.com/inward/record.url?scp=42449089833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449089833&partnerID=8YFLogxK

U2 - 10.2174/138955708783744074

DO - 10.2174/138955708783744074

M3 - Review article

C2 - 18336345

AN - SCOPUS:42449089833

SN - 1389-5575

VL - 8

SP - 248

EP - 255

JO - Mini-Reviews in Medicinal Chemistry

JF - Mini-Reviews in Medicinal Chemistry

IS - 3

ER -

Strategies for in vivo siRNA delivery in cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this